Kaili Fu
Impact in
- Oncology top 10%
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 10%
- Protease and Inhibitor Mechanisms
Papers in
-
- Venous Thromboembolism Diagnosis and Management 3
- Oncology 13
- Cancer Immunotherapy and Biomarkers 7
- Peptidase Inhibition and Analysis 6
- Co-authors
- Haojun ChenQin LinLiang ZhaoLong SunYizhen PangHua WuJianhao ChenJun Yu
- Journals
- European Journal of Nuclear Medicine and Molecular Imaging (3 papers)International Journal of Pharmaceutics (2 papers)Theranostics (2 papers)Molecular Cancer Therapeutics (1 paper)Clinical and Experimental Hypertension (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Kaili Fu
29 papers receiving 813 citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 435
- Cancer Research 161
- Radiology, Nuclear Medicine and Imaging 161
- Surgery 256
- Periodontics 22
Countries citing papers authored by Kaili Fu
This map shows the geographic impact of Kaili Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaili Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaili Fu more than expected).
Fields of papers citing papers by Kaili Fu
This network shows the impact of papers produced by Kaili Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaili Fu. The network helps show where Kaili Fu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kaili Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 11 | |
| 2 | 2024 | 7 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 1 | |
| 5 | Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice Hit paper breakdown → | 2024 | 120 |
| 6 | 2024 | 3 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 25 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 0 | |
| 11 | Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review Hit paper breakdown → | 2022 | 128 |
| 12 | 2022 | 78 | |
| 13 | 2021 | 7 | |
| 14 | 2021 | 31 | |
| 15 | 2020 | 24 | |
| 16 | 2020 | 25 | |
| 17 | 2019 | 11 | |
| 18 | 2015 | 8 | |
| 19 | 2015 | 2 | |
| 20 | 2012 | 36 |
About Kaili Fu
Kaili Fu is a scholar working on Internal Medicine, Oncology, Biotechnology, Cancer Research and Cardiology and Cardiovascular Medicine, having authored 32 papers that have together received 820 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Peptidase Inhibition and Analysis (6 papers), Helicobacter pylori-related gastroenterology studies (5 papers), Protease and Inhibitor Mechanisms (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers), Nanoplatforms for cancer theranostics (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cancer Research and Treatments (3 papers). The work is most often cited by research in Oncology (435 citations), Cancer Research (161 citations), Radiology, Nuclear Medicine and Imaging (161 citations), Surgery (256 citations) and Periodontics (22 citations). Kaili Fu has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Haojun Chen, Qin Lin, Liang Zhao, Long Sun, Yizhen Pang, Hua Wu, Jianhao Chen, Jun Yu, Ka‐Fai To and Qihang Shang. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, International Journal of Pharmaceutics, Theranostics, Molecular Cancer Therapeutics and Clinical and Experimental Hypertension.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.